Methods and compositions related to a BRAF mutation and microsatellite stability
Disclosed are methods and compositions related to a BRAF mutation and microsatellite stability.
1. A method of prognosing survival rates in a human subject diagnosed with a stage II colon cancer, comprising: a) amplifying via PCR a nucleic acid sample obtained from a tumor isolated from the subject and detecting amplification of a microsatellite panel comprising BAT26 and TGFBRII with agents that specifically identify said microsatellite panel members to measure microsatellite stability; b) assaying a tumor sample isolated from the human subject to detect the presence of a BRAF mutation in the sample, wherein the BRAF mutation is determined using a forward primer and a reverse primer; and wherein the forward primer is 5′-TCATAATGCTTGCTCTGATAGGA (SEQ ID NO: 1) and the reverse primer is 3′-CTTTCTAGTAACTCAGCAGC (SEQ ID NO: 2); and wherein the BRAF mutation comprises V600E; and c) prognosing a decreased survival rate of the subject diagnosed with stage II colon cancer by determining the presence of microsatellite stability and a presence of a BRAF mutation in steps a) and b).
2. The method of claim 1 , wherein the survival rate is measured by American Joint Committee on Cancer stage designation.
3. The method of claim 1 , wherein the survival rate is measured by the percentage of chance for five-year survival.
4. The method of claim 3 , wherein the chance of survival is greater than 10%.
5. The method of claim 3 , wherein the chance of survival is greater than 20%.
6. A method of classifying severity of colon cancer in a human subject diagnosed with a stage II disease, comprising a) amplifying via PCR a nucleic acid sample obtained from a tumor isolated from the subject and detecting amplification of a microsatellite panel comprising BAT26 and TGFBRII with agents that specifically identify said microsatellite panel members to measure microsatellite stability; b) assaying a tumor sample isolated from the subject to determine the presence of a BRAF mutation in the sample, wherein the BRAF mutation is determined using a forward primer and a reverse primer; and wherein the forward primer is 5′-TCATAATGCTTGCTCTGATAGGA (SEQ ID NO: 1) and the reverse primer is 3′-CTTTCTAGTAACTCAGCAGC (SEQ ID NO: 2); and wherein the BRAF mutation comprises V600E; and c) classifying the colon cancer as aggressive in subjects having stage II colon cancer expressing microsatellite stability and a BRAF mutation when compared to tumor samples expressing microsatellite stability and wild type BRAF.